Novel Application of Pentabromobenzyl Column for Simultaneous Determination of Eight Antifungal Drugs Using High-performance Liquid Chromatography

Author(s): Maha M. Abou El-Alamin, Maha A. Sultan, Mostafa A. Atia, Hassan Y. Aboul-Enein*

Journal Name: Combinatorial Chemistry & High Throughput Screening
Accelerated Technologies for Biotechnology, Bioassays, Medicinal Chemistry and Natural Products Research

Volume 23 , Issue 10 , 2020

Become EABM
Become Reviewer
Call for Editor


Aim: A new, accurate and sensitive reversed-phase high-performance liquid chromatography (RP-HPLC) as an analytical method for the quantitative determination of eight antifungal drugs in spiked human plasma has been described optimized and validated.

Materials and Methods: The analyzed compounds were voriconazole (VOR), luliconazole (LUL), clotrimazole (CLO), tioconazole (TIO), posaconazole (POS), ketoconazole (KET), sertaconazole (SER) and terconazole (TER).

Results: The separation of the analyzed compounds was conducted using a novel pentabromobenzyl column known as COSMOSIL PBB-R (150 mm × 4.6 mm I.D., particle size 5 μm). The analysis of the studied drugs was determined within 14 min using a diode array detector and the mobile phase consisted of: 10 mM potassium dihydrogen phosphate buffer (pH 2.1): Methanol (2: 98 v/v). A linear response was observed for all compounds in the range of concentration studied. Sample preparation was done through liquid-liquid extraction using diethyl ether.

Conclusion: This proposed method was validated in terms of linearity, limit of quantification, limit of detection, accuracy, precision and selectivity. The method was successfully applied for the determination of these drugs in their pharmaceutical formulations and in human plasma samples.

Keywords: HPLC, pentabromobenzyl column, antifungal drugs, pharmaceutical analysis, biomedical analysis, liquid chromatography.

Sweetman, S.C. Martindale: The Complete Drug Reference. 38th ed; Pharmaceutical Press: UK, 2014.
Li, Y.; Theuretzbacher, U.; Clancy, C.J.; Nguyen, M.H.; Derendorf, H. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin. Pharmacokinet., 2010, 49(6), 379-396.
[] [PMID: 20481649]
Hassan, R.Y.A.; Sultan, M.A.; El‐Alamin, M.M.A.; Atia, M.A.; Aboul‐Enein, H.Y. A Disposable carbon nanotubes‐screen printed electrode (CNTs‐SPE) for determination of the antifungal agent posaconazole in biological samples. Electroanalysis, 2017, 29, 843-849.
Sultan, M.A.; Abou El-Alamin, M.M.; Atia, M.A.; Aboul-Enein, H.Y. Spectrophotometric and fluorimetric determination of posaconazole in dosage form and spiked human plasma. Indo Am. J. Pharm. Res., 2016, 6(9), 6573-6582.
Sultan, M.A.; Abou El-alamin, M.M.; Atia, M.A.; Aboul-Enein, H.Y. Stability-indicating methods for the determination of luliconazole by TLC and HPTLC – Densitometry in bulk powder and cream dosage f orm. J. Planar Chromatogr. Mod. TLC, 2017, 30(1), 68-74.
Stevenson, P.G.; Kayillo, S.; Dennis, G.R.; Shalliker, R.A. Effects of π‐π interactions on the separation of PAHs on Phenyl‐type stationary phases. J. Liq. Chromatogr. Relat. Technol., 2008, 31(3), 324-347.
Kahle, K.; Langmann, P.; Schirmer, D.; Lenker, U.; Keller, D.; Helle, A.; Klinker, H.; Heinz, W.J. Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography. Antimicrob. Agents Chemother., 2009, 53(7), 3140-3142.
[] [PMID: 19380591]
Turowski, M.; Morimoto, T.; Kimata, K.; Monde, H.; Ikegami, T.; Hosoya, K.; Tanaka, N. Selectivity of stationary phases in reversed-phase liquid chromatography based on the dispersion interactions. J. Chromatogr. A, 2001, 911(2), 177-190.
[] [PMID: 11293579]
Melander, W.R.; Chen, B-K.; Horvàth, C.J. Mobile phase effects in reversed-phase chromatography. J. Chromatogr. A, 1979, 185, 93-109.
Poppe, H.; Kraak, J.C.; Huber, J.F.K.; van den Berg, J.H.M. Temperature gradients in HPLC columns due to viscous heat dissipation. Chromatographia, 1981, 14, 515-523.
ICH Topic Q 2 (R1). Validation of Analytical Procedures; Text and Methodology European Medicine Agency: London, US, 1995.
BP. The British Pharmacopoeia Her majesty’s Stationery Office; Vallender M.: London, 2016.
Sonawane, S.; Gide, P. Application of experimental design for the optimization of forced degradation and development of a validated stability-indicating LC method for luliconazole in bulk and cream formulation. Arab. J. Chem., 2016, 9(2), S1428-S1434.
Hamdy, D.A.; Belal, T.S. A Comparative study of newly developed HPLC-DAD and UHPLC-UV assays for the determination of posaconazole in bulk powder and suspension dosage form. J. Anal. Methods Chem., 2014.2014241035
[] [PMID: 25258695]
US. The United States Pharmacopeia USP 39 National Formula 34 United States Pharmacopeial Convention: Rockville, United States, 2016.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [991 - 1001]
Pages: 11
DOI: 10.2174/1386207323666200220114818
Price: $65

Article Metrics

PDF: 30